Biology of LOX-1 in relation to atherogenesis

Future Lipidology

Volumn 3, Issue 6, 2008, Pages 689-696

  Hu, Changping ^a,b   Mehta, Jawahar L ^c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Atherosclerosis; Collagen; Extracellular matrix; LOX 1; Matrix metalloproteinase; NADPH oxidose; Oxidative stress

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN II; COLLAGEN; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; MATRIX METALLOPROTEINASE; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA;

ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD COMPONENT; CELL MIGRATION; CELL PROLIFERATION; DIABETES MELLITUS; DOWN REGULATION; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE DELETION; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INFLAMMATION; ISCHEMIC HEART DISEASE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; SMOOTH MUSCLE FIBER; STROKE; THROMBOGENESIS; UPREGULATION; VASCULAR SMOOTH MUSCLE;

EID: 67249129600     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.3.6.689     Document Type: Review

References (54)

1. Landmesser U, Hornig B, Drexler H: Endothelial function: a critical determinant in atherosclerosis? Circulation 109, 1127-1133 (2004).
2. Virani SS, Polsani VR, Nambi V: Novel markers of inflammation in atherosclerosis. Curr. Atheroscler. Rep. 10, 164-170 (2008).
3. Schulze PC, Lee RT: Oxidative stress and atherosclerosis. Curr. Atheroscler. Rep. 7, 242-248 (2005).
4. McCord JM: Oxygen-derived radicals: a link between reperfusion injury and inflammation. Fed. Proc. 46, 2402-2406 (1987).
5. Matsuura E, Kobayashi K, Tabuchi M, Lopez LR: Oxidative modification of low-density lipoprotein and immune regulation of atherosclerosis. Prog. Lipid. Res. 45, 466-486 (2006).
6. Mehta JL: Oxidized or native low-density lipoprotein cholesterol: which is more important in atherogenesis? J. Am. Coll. Cardiol. 48, 980-982 (2006).
7. Li D, Mehta JL: Antisense to LOX-1 inhibits oxidized LDL-mediated upregulation of monocyte chemoattractant protein-1 and monocyte adhesion to human coronary artery endothelial cells. Circulation 101, 2889-2895 (2000).
8. Li D, Chen H, Sawamura T. Saldeen T, Mehta JL: Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J. Pharmacol. Exp. Ther. 302, 601-605 (2002).
9. Erl W, Weber PC, Weber C: Monocytic cell adhesion to endothelial cells stimulated by oxidized low-density lipoprotein is mediated by distinct endothelial ligands. Atherosclerosis 136 297-303 (1998).
10. Li D, Liu L, Chen H, Sawamura T, Mehta JL: LOX-1, an oxidized LDL endothelial receptor, induces CD40/CD40L signaling in human coronary artery endothelial cells. Arterioscler. Thromb. Vasc. Biol. 23, 816-821 (2003).
11. Li D, Liu L, Chen H, Sawamura T, Ranganathan S, Mehta JL: LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation 107, 612-617 (2003).
12. Chen K, Chen J, Liu Y et al.: Adhesion molecule expression in fibroblasts: alteration in fibroblast biology after transfection with LOX-1 plasmids. Hypertension 46, 622-627 (2005).
13. Cominacini L, Pasini AF, Garbin U, Davoli A, Tosetti ML, Sawamura T: Oxidized low density lipoprotein (Ox-LDL) binding to Ox-LDL receptor-1 in endothelial cells induces the activation of NF-κB through an increased production of intracellular reactive oxygen species. J. Biol. Chem. 275, 12633-12638 (2000).
14. Chavalds E, Dernbach E, Dimmeler S: LDL oxidized inhibits vascular endothelial growth factor-induced endothelial cell migration by an inhibitory effect on the Akt/endothelial nitric oxide synthase pathway. Circulation 103, 2102-2107 (2001).
15. Dhaliwal BS, Steinbrecher UP: Scavenger receptors and oxidized low density lipoproteins. Clin. Chim. Acta. 286, 191-205 (1999).
16. Sawamura T, Kume N, Aoyama T et al.: An endothelial receptor for oxidized low-density lipoprotein. Nature 386, 73-77 (1997).
17. Mehta JL, Li DY: Identification and autoregulation of receptor for OX-LDL in cultured human coronary artery endothelial cells. Biochem. Biophys. Res. Commun. 248, 511-514 (1998).
18. Aoyama T, Fujiwara H, Masaki T, Sawamura T: Induction of lectin-like oxidized LDL receptor by oxidized LDL and lysophosphatidylcholine in cultured endothelial cells. J. Mol. Cell. Cardiol. 31, 2101-2114 (1999).
19. Bickel PE, Freeman M: Rabbit aortic smooth muscle cells express inducible macrophage scavenger receptor messenger RNA that is absent from endothelial cells. J. Clin. Invest. 90, 1450-1457 (1992).
20. Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G: Lectin-like oxidized-low density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc. Res. 69, 36-45 (2006).
21. Xu X, Gao X, Potter BJ, Cao JM, Zhang C: Anti-LOX-1 rescues endothelial function in coronary arterioles in atherosclerotic ApoE knockout mice. Arterioscler. Thromb. Vasc. Biol. 27, 871-877 (2007).
22. Mehta JL, Sanada N, Hu CP et al.: Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ. Res. 100, 1634-1642 (2007).
23. Li D, Saldeen T, Romeo F, Mehta JL: Oxidized LDL upregulates angiotensin II type 1 receptor expression in cultured human coronary artery endothelial cells. the potential role of transcription factor NF-κB. Circulation 102, 1970-1976 (2000).
24. Li D, Singh RM, Liu L et al.: Oxidized-LDL through LOX-1 increases the expression of angiotensin converting enzyme in human coronary artery endothelial cells. Cardiovasc. Res. 37, 238-243 (2003).
25. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM: Renin-angiotensin system and cardiovascular risk. Lancet 369, 1208-1219 (2007).
26. Draude G, Lorenz RL: The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin. Biochem. Pharmacol. 57, 383-386 (1999).
27. Shin HK, Kim YK, Kim KY, Lee JH, Hong KW: Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: prevention by cilostazol. Circulation 109, 1022-1028 (2004).
28. Chen M, Kakutani M, Naruko T: Activation-dependent surface expression of LOX-1 in human platelets, Biochem. Biophys. Res. Commun. 282, 153-158 (2001).
29. Marwali MR, Hu CP, Mohandas B et al.: Modulation of ADP-induced platelet activation by aspirin and pravastatin: role of lectin-like oxidized low-density lipoprotein receptor-1, nitric oxide, oxidative stress and inside-out integrin signaling. J. Pharmacol. Exp. Ther. 322, 1324-1332 (2007).
30. Chen K, Chen J, Li D, Zhang X, Mehta JL: Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-γ ligand pioglitazone. Hypertension 44, 655-661 (2004).
31. Chen J, Liu Y, Liu H, Hermonat PL, Mehta JL: Molecular dissection of angiotensin II-activated human LOX-1 promoter. Arterioscler. Thromb. Vasc. Biol. 26, 1163-1168 (2006).
32. Sorescu D: Smad3 mediates angiotensin II- and TGF-β1-induced vascular fibrosis: Smad3 thickens the pior. Circ. Res. 98, 988-989 (2006).
33. Hu C, Dandapat A, Sun L et al.: Regulation of TGFβ1-mediated collagen formation by LOX-1: studies based on forced overexpression of TGFβ1 in wild-type and LOX-1 knockout mouse cardiac fibroblasts. J. Biol. Chem. 283, 10226-10231 (2008).
34. Clerk A, Sudden PH: Inflame my heart (by p38-MAP). Circ. Res. 99, 455-458 (2006).
35. Ishigaki Y, Katagiri H, Gao J et al.: Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 118, 75-83 (2008).
36. Inoue K, Arai Y, Kurihara H, Kita T, Sawamura T: Overexpression of lectin-like oxidized low-density lipoprotein receptor-1 induces intramyocardial vasculopathy in apolipoprotein E-null mice. Circ. Res. 97, 176-184 (2005).
37. Jacob MP, Badier-Commander C, Fontaine V, Benazzoug Y, Feldman L, Michel JB: Extracellular matrix remodeling in the vascular wall. Pathol. Biol. 49, 326-332 (2001).
38. Cuaz-Pérolin C, Jguirim I, Lariqauderie G et al.: Apolipoprotein E knockout mice over-expressing human tissue inhibitor of metalloproteinase 1 are protected against aneurysm formation but not against atherosclerotic plaque development. J. Vasc. Res. 43, 493-501 (2006).
39. Shah PK: Pathophysiology of plaque rupture and the concept of plaque stabilization. Cardiol. Clin. 14, 17-29 (1996).
40. Kunz J: Matrix metalloproteinases and atherogenesis in dependence of age. Gerontology 53, 63-73 (2007).
41. Rekhter MD: Collagen synthesis in atherosclerosis: too much and not enough. Cardiovasc. Res. 41, 376-384 (1999).
42. Hu CP, Dandapat A, Liu Y, Hermonat PL, Mehta JL: Blockade of hypoxia-reoxygenation-mediated collagen type I expression and MMP activity by over-expression of TGF-β1 in mouse cardiomyocytes. Am. J. Physiol. Heart. Circ. Physiol. 293, H1833-H1838 (2007).
43. Hu C, Dandapat A, Chen J et al.: LOX-1 deletion alters signals of myocardial remodeling immediately after ischemia-reperfusion. Cardiovasc. Res. 76, 292-302 (2007).
44. Hu C, Dandapat A, Sun L et al.: Modulation of angiotensin II-mediated hypertension and cardiac remodeling by lectin-like oxidized low-density lipoprotein receptor-1 deletion. Hypertension 52(3), 556-562 (2008).
45. Hu C, Dandapat A, Sun L et al.: LOX-1 deletion decreases collagen accumulation in atherosclerotic plaque in low-density lipoprotein receptor knockout mice fed a high-cholesterol diet. Cardiovasc. Res. 79, 287-293 (2008).
46. Ishino S, Mukai T, Kume N et al.: Lectin-like oxidized LDL receptor-1 (LOX-1) expression is associated with atherosclerotic plaque instability -analysis in hypercholesterolemic rabbits. Atherosclerosis 195, 48-56 (2007).
47. Saini HK, Xu YJ, Arneja AS, Tappia PS, Dhalla NS: Pharmacological basis of different targets for the treatment of atherosclerosis. J. Cell. Mol. Med. 818-839 (2005).
48. Böhm M: Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now? Am. J. Cardiol. 100, 38J-44J (2007).
49. Tenenbaum A, Fisman EZ, Motro M, Adler Y: Optimal management of combined dyslipidemia: what have we behind statins monotherapy? Adv. Cardiol. 45, 127-153 (2008).
50. Tahara N, Kai H, Ishibashi M et al.: Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J. Am. Coll. Cardiol. 48, 1825-1831 (2006).
51. Chen J, Li D, Schaefer R, Mehta JL: Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan. Atherosclerosis 184, 295-301 (2006).
52. Kobayashi N, Honda T, Yoshida K et al.: Critical role of bradykinin-eNOS and oxidative stress-LOX-1 pathway in cardiovascular remodeling under chronic angiotensin-converting enzyme inhibition. Atherosclerosis 187, 92-100 (2006).
53. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104, 365-372 (2001).
54. Rekhter M: Vulnerable atherosclerotic plaque: emerging challenge for animal models. Curr. Opin. Cardiol. 17, 626-632 (2002).